上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
BAM7 纯度: 99.18%
BAM7 是一种直接的选择性 BAX 激活剂,IC50 为 3.3 μM。
BAM7 Chemical Structure
CAS No. : 331244-89-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1191 | In-stock | |
10 mg | ¥1083 | In-stock | |
50 mg | ¥4938 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
BAM7 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Anti-Cancer Compound Library
- Targeted Diversity Library
生物活性 |
BAM7 is a direct and selective activator of proapoptotic BAX with an IC50 of 3.3 μM. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
BAM7 is selective for the BH3-binding site on BAX. BAM7 activates BAX and BAX-dependent cell death. Whereas treatment with BAX or BAM7 alone has no effect on the liposomes, the combination of BAM7 and BAX yields dose-responsive liposomal release of entrapped fluorophore. BAM7 dose- and time-responsively impairs the viability of Bak-/- MEFs that exclusively express BAX but has no effect on Bak-/- MEFs that contain BAK but lack BAX. In contrast, standard proapoptotic stimuli such as serum withdrawal, Staurosporine and Etoposide induces an equivalent apoptotic response in Bax-/- and Bak-/- MEFs. As further evidence of BAM7 specificity of action, (i) BAM7 does not affect the viability of Bax-/- Bak-/- MEFs; (ii) ANA-BAM16, which does not bind or activate BAX, has no effect on Bak-/- MEFs; and (iii) BAM7 selectively induces cell death of Bax-/- Bak-/- MEFs reconstituted with wild-type BAX but not BAXK21E , which bears the mutation that abrogates BAM7 binding[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
405.47 |
||||||||||||||||
Formula |
C21H19N5O2S |
||||||||||||||||
CAS 号 |
331244-89-4 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 5 mg/mL (12.33 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
|
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
MEF cells are maintained in DMEM high glucose supplemented with 10% (v/v) FBS, 100 U/mL Penicillin, 100 μg/mL Streptomycin, 2 mM L-glutamine, 50 mM HEPES, 0.1 mM MEM nonessential amino acids and 50 μM β-mercaptoethanol. MEFs (2.5×103 cells per well) are seeded in 96-well opaque plates for 18-24 h and then incubated with serial dilutions of BAM7 (3.75, 5, 7.5, 10 and 15 μM), ANA-BAM16 or vehicle (0.15% (v/v) DMSO) in DMEM at 37°C in a final volume of 100 μL. Cell viability is assayed at 24 h by addition of CellTiter-Glo reagent, and luminescence is measured using a SpectraMax M5 microplate reader. Viability assays are performed in at least triplicate, and the data are normalized to vehicle-treated control wells[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务